查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916874

环肽库市场按类型、产品形式、方法、给药途径、应用和最终用户划分－全球预测（2026-2032 年）

Cyclic Peptide Library Market by Type, Product Format, Method, Route Of Administration, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，环肽库市场价值将达到 34.2 亿美元，到 2026 年将成长至 37.5 亿美元，到 2032 年将达到 98.6 亿美元，复合年增长率为 16.32%。

主要市场统计数据
基准年 2025 34.2亿美元
预计年份：2026年 37.5亿美元
预测年份：2032年 98.6亿美元
复合年增长率 (%) 16.32%

透过结构和功能优势，明确环状胜肽库在现代药物发现流程和转化研究中的战略作用。

环肽库已从学术实验室中的一种小众工具发展成为药物发现和转化研究流程中的战略资产，重塑了研究人员进行标靶结合、分子设计和先导药物最适化的方式。本文回顾了环肽的科学基础和实际效用，重点介绍了其结构优势，例如构象限制、更高的靶点特异性以及通常优于线性胜肽的代谢稳定性。此外，近年来展示技术、合成方法和计算建模的进步拓展了环肽的应用范围，使其能够对以往难以处理的复杂靶点类别进行高通量分析。

筛检、结构测定和临床应用的进展如何融合，将重塑环肽类药物的发现模式

环肽研究领域正受到技术、方法和市场主导因素的共同作用而重塑，并由此带来变革性转变。首先，组合文库设计和高通量筛检的创新使得研究人员能够精准地探索更大、更多样化的化学空间，从而提高了针对复杂靶点的配体发现潜力。同时，质谱分析、基于片段的方法以及机器学习驱动的序列-功能模型的进步，使得研究人员能够快速註释先导化合物并早期预测其开发潜力，从而简化了先导化合物化合物的筛选过程。

评估2025年美国关税如何推动胜肽类研究生态系统的供应链重组与策略营运调整

美国2025年实施的政策调整和关税措施，为环肽研究供应链的各个环节带来了新的营运复杂性，其累积影响涵盖了从原材料采购到契约製造和合作研究协议的各个方面。更高的关税和更严格的程序要求增加了某些试剂和特殊耗材的进口成本，迫使采购团队寻求供应商多元化并重新评估库存策略。为此，许多实验室正在延长采购前置作业时间，尽可能储备关键试剂，并寻找合格的替代供应商，以确保筛检宣传活动和合成作业的连续性。

深入的细分市场分析揭示了生物化学研究、结构生物学和治疗亚领域如何以独特的方式推动环肽药物的发现和开发重点。

环肽研究的各个细分领域趋势揭示了不同的驱动因素和技术需求，这些因素会影响投资重点和专案设计。在生物化学研究领域，基础检测方法的开发和标靶结合研究建构了后续药物发现活动所需的基础知识，而结构生物学研究则利用晶体学和核磁共振技术来阐明结合模式和构象动态。这些基础性研究共同支撑着合理的化合物库建构和后续筛检决策。

美洲、欧洲、中东和非洲以及亚太地区的区域创新丛集和基础设施会影响营运选择和伙伴关係策略。

区域趋势对环肽生态系统的人才取得、基础设施、监管互动和伙伴关係机会都有显着影响。在美洲，强大的转化基础设施、密集的生物技术丛集和整合的临床网络促进了药物从发现到早期临床评估的快速进展。这些生态系统的特点是接近性资本、拥有广泛的CRO（受託研究机构）和CDMO（合约开发和生产组织）服务，以及许多促进技术转移和商业化的倡议合作。因此，在该地区运营的机构通常会优先考虑快速迭代和与临床相关人员的密切合作。

一个独特的生态系统汇集了平台创新者、转化生物技术公司和专业服务供应商，从而促进环肽药物的发现和开发。

环肽技术的竞争格局是一个由成熟的药物研发团队、专业生物技术公司、平台提供者和服务机构组成的相互关联的生态系统。提供展示技术、高效合成和整合筛检服务的平台提供者对于提高药物发现效率至关重要，而合成化学创新者和分析专家则为将先导化合物转化为候选治疗药物所需的开发性提供见解。学术创业公司和敏捷的生物技术公司通常推动早期新颖性和应用导向创新，将机制见解转化为差异化的化合物库设计和标靶策略。

领导者可以采取切实有效、影响深远的策略行动，以降低环肽计画的风险，并加速其从发现到临床准备的进程。

产业领导者应优先采取果断行动，以增强韧性、加速转化进程并最大化其环肽计画的策略价值。首先，应儘早将结构生物学与高品质的生物物理检验相结合，以降低后续研发的失败率并指南合理的化合物库设计。早期投入资源进行正交检验和结构确认，可以显着提高先导化合物筛选的信噪比，并将药物化学研究集中在最有前景的骨架上。

一种透明且可重复的调查方法，结合了专家访谈、技术文献综合和透过三角测量法进行的分析检验。

本研究采用严谨的分析框架，整合一手和二手讯息，对环肽的现况得出平衡且可重复的结论。一手研究包括对来自学术机构、生技公司、合约服务机构和转化研究领域的科学研究和商业领袖进行结构化访谈，以深入了解技术应用、营运挑战和伙伴关係动态。此外，还对同行评审文献、专利概况、会议报告和官方监管指南进行了技术审查，以佐证研究观察结果，并结合已记录的科学进展和政策背景。

整合策略要务和营运经验，建立将环肽发现转化为临床和商业性影响的综合管道

环肽库融合了化学、结构生物学和转化策略，为解决棘手标靶和治疗难题提供了极具吸引力的机会。本文综合的证据表明，成功并非仅取决于单一的技术能力，而是需要一种整合策略，将稳健的库设计、早期结构检验和营运韧性相结合。此外，从影响供应链的政策变化到区域产能缺口等外部环境因素，都将对专案执行和伙伴关係的选择产生重大影响。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章：环肽库市场（按类型划分）

  • 合成环肽
  • 天然环肽

9. 依产品形式分類的环状胜肽库市场

  • 脂肽
  • 环肽
  • 环状二胜二肽

第十章 依方法论分類的环肽库市场

  • 固相胜肽合成
  • 重组生物合成
  • 液相胜肽合成
  • 混合技术

第十一章 依给药途径分類的环肽库市场

  • 外用
  • 口服
  • 注射

第十二章：环肽库市场（按应用领域划分）

  • 治疗
  • 研究与开发
  • 环境保护
  • 诊断生物感测器

第十三章：依最终用户分類的环肽库市场

  • 製药公司
  • 合约研究与製造组织
  • 生技公司
  • 学术研究机构

第十四章 环肽库市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 环肽库市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国环肽库市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国环胜肽库市场

第十七章：中国环肽库市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics Ltd
  • Boehringer Ingelheim International GmbH
  • Evotec SE
  • Merck & Co., Inc.
  • Novartis AG
  • PeptiDream Inc.
  • Pfizer Inc.
  • Roche Holding AG
Product Code: MRR-AE420CB153C5

The Cyclic Peptide Library Market was valued at USD 3.42 billion in 2025 and is projected to grow to USD 3.75 billion in 2026, with a CAGR of 16.32%, reaching USD 9.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.42 billion
Estimated Year [2026] USD 3.75 billion
Forecast Year [2032] USD 9.86 billion
CAGR (%) 16.32%

Defining the strategic role of cyclic peptide libraries in modern discovery pipelines and translational research through structural and functional advantages

Cyclic peptide libraries have moved from niche tools in academic labs to strategic assets for discovery and translational pipelines, shaping how researchers approach target engagement, molecular design, and lead optimization. This introduction frames the scientific foundations and practical utility of cyclic peptides, highlighting their structural advantages such as conformational constraint, enhanced target specificity, and often improved metabolic stability relative to linear counterparts. In addition, recent advances in display technologies, synthetic methods, and computational modeling have broadened the scope of cyclic peptide applications, enabling high-throughput interrogation of complex target classes previously considered intractable.

Beyond chemistry, the integration of cyclic peptide libraries with biophysical screening, structural determination techniques, and cell-based functional assays has reconfigured typical workflows. Teams now layer orthogonal validation steps early in discovery to de-risk hits and accelerate progression into optimization. As a consequence, program timelines are shifting toward modular, evidence-driven pipelines that prioritize on-target engagement and translatability. This evolution is particularly salient for organizations balancing exploratory research and translational outcomes, since cyclic peptides often serve as bridging modalities between small molecules and biologics, offering unique pharmacological profiles that can address unmet therapeutic needs.

Importantly, stakeholders must navigate a complex ecosystem that includes academic innovation, service providers, and platform developers. Cross-disciplinary collaboration and early investment in robust analytical and screening capacity are essential to extracting maximum value from cyclic peptide strategies. This introduction sets the stage for deeper analysis of the technological shifts, regulatory and policy considerations, segmentation dynamics, and regional variation that follow, framing cyclic peptide libraries as a pivotal element of modern discovery and therapeutic design.

How converging advances in screening, structural determination, and translational practice are reshaping discovery paradigms for cyclic peptide modalities

The landscape for cyclic peptide research is being reshaped by a convergence of technological, methodological, and market-driven forces that together constitute transformative shifts. First, innovations in combinatorial library design and high-throughput screening are enabling larger and more diverse chemical space to be explored with better fidelity, which in turn increases the probability of identifying ligands for challenging targets. Concurrently, improvements in mass spectrometry, fragment-based methods, and machine learning-driven sequence-to-function models are enabling rapid annotation of hits and early prediction of developability profiles, smoothing the path toward lead selection.

Second, structural biology advancements are creating new opportunities for rational cyclic peptide design. Enhanced cryo-electron microscopy, crystallography pipelines, and integrative modeling techniques now allow teams to visualize peptide-protein interactions at higher resolution and in more native-like contexts. As a result, structural insights are increasingly driving the iterative optimization cycle, reducing reliance on blind screening and accelerating hypothesis-driven chemistry.

Third, the regulatory and translational environment is adapting to accommodate peptides as distinct therapeutic modalities. Regulatory pathways, clinical trial designs, and formulation strategies are evolving in response to unique pharmacokinetic and delivery challenges that cyclic peptides present. Consequently, organizations are investing earlier in ADME profiling, stability testing, and targeted delivery approaches, recognizing that these investments materially influence program viability. Taken together, these shifts are altering how discovery programs are prioritized, resourced, and executed across academic, biotech, and industrial settings.

Assessment of how the 2025 United States tariff measures are inducing supply chain realignment and strategic operational adaptations across peptide research ecosystems

Policy shifts and tariff measures introduced by the United States in 2025 have introduced a new layer of operational complexity across the cyclic peptide research supply chain, with cumulative effects felt from raw material procurement to contract manufacturing and collaborative research arrangements. The increased duties and procedural requirements have elevated inbound costs for certain reagents and specialized consumables, prompting procurement teams to reassess supplier diversification and inventory strategies. In response, many laboratories are extending procurement lead times, stockpiling critical reagents where feasible, and qualifying alternative suppliers to maintain continuity of screening campaigns and synthetic operations.

Moreover, service providers that rely on international supply chains have adjusted pricing models and contractual terms to reflect higher compliance overhead and variable lead times. This has influenced the economics of outsourcing discovery activities, with some organizations bringing capabilities in-house to manage costs and timelines while others renegotiate service-level agreements to include contingency provisions. Regulatory compliance and customs complexity have also driven investment in supply chain transparency and enhanced vendor auditing to reduce the risk of disruptions.

Beyond immediate procurement effects, tariff-driven uncertainty has prompted strategic reconsideration of geographic sourcing, partnership structures, and manufacturing footprints. Organizations are increasingly weighing nearshoring or regional manufacturing partnerships to mitigate tariff exposure, particularly for late-stage peptide production where regulatory inspection alignment and quality assurance are critical. These adjustments highlight that policy instruments intended to address broad economic objectives can have cascading operational and strategic impacts on specialized research ecosystems, necessitating proactive mitigation and adaptive planning across the industry.

Deep segmentation analysis revealing how biochemical research, structural biology, and therapeutic subdomains uniquely drive cyclic peptide discovery and development priorities

Segment-level behavior within cyclic peptide research reveals differentiated drivers and technical requirements that influence investment priorities and program design. In biochemical research contexts, foundational assay development and target engagement studies create the baseline understanding necessary for subsequent discovery activities, while structural biology efforts leverage crystallography and nuclear magnetic resonance methodologies to resolve binding poses and conformational dynamics. Together these foundational disciplines inform rational library construction and inform downstream screening decisions.

In the drug discovery segment, activities bifurcate into hit identification and lead optimization phases, where high-throughput screening and hit triage converge with medicinal chemistry and iterative optimization to improve affinity, selectivity, and pharmacokinetic properties. This progression is tightly linked to structural biology outputs and analytical characterization, forming a feedback loop that accelerates decision-making. Within therapeutics development, multiple clinical domains show unique needs and challenges: cardiovascular applications focus on indications such as heart failure and hypertension with an emphasis on safety and chronic dosing profiles, infectious disease work spans bacterial, fungal, and viral targets where potency and resistance profiles are paramount, and oncology efforts address both hematological malignancies and solid tumor contexts where delivery, tumor penetration, and target specificity drive program design.

These segmentation dynamics underscore the importance of cross-functional expertise; success often depends on integrating biochemical, structural, and translational perspectives early in program initiation. Additionally, platform choices-whether based on display technologies, synthetic libraries, or computationally designed cyclic motifs-must align with the segment-specific objectives and downstream clinical requirements to maximize translational potential.

How regional innovation clusters and infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific shape operational choices and partnership strategies

Regional dynamics exert a meaningful influence on access to talent, infrastructure, regulatory engagement, and partnership opportunities across the cyclic peptide ecosystem. In the Americas, strong translational infrastructure, dense biotech clusters, and integrated clinical networks facilitate rapid progression from discovery to early clinical evaluation. These ecosystems are characterized by proximity to capital, broad CRO and CDMO services, and numerous academic-industry partnerships that catalyze technology transfer and commercialization initiatives. Consequently, organizations operating here often prioritize rapid iteration and close collaboration with clinical stakeholders.

In Europe, the Middle East & Africa region, diverse regulatory regimes and a mixture of advanced academic centers with emerging biotech hubs create both opportunities and complexities. Fragmented regulatory pathways can slow pan-regional deployment, but centers of excellence in structural biology and peptide chemistry provide deep technical capabilities. Strategic alliances and translational consortia are common approaches to bridge capability gaps and accelerate access to specialized services. Policymakers and funders in several jurisdictions are also enabling innovation through targeted grants and translational programs aimed at de-risking early-stage modalities.

In the Asia-Pacific region, rapidly maturing biopharma clusters, growing contract service capacity, and competitive manufacturing ecosystems are reshaping global sourcing strategies. Organizations in this region are rapidly scaling analytical and manufacturing capabilities for peptides and are increasingly central to global supply chains. Collaboration models often emphasize cost-efficiency and volume capability, while rising investments in local talent and infrastructure are enabling more advanced discovery activities to be undertaken regionally. Collectively, these regional characteristics influence partner selection, operational design, and strategic investment decisions across the industry.

Characterization of the ecosystem where platform innovators, translational biotechs, and specialized service providers converge to enable cyclic peptide discovery and development

The competitive landscape for cyclic peptide technologies is characterized by a mixture of established pharmaceutical research groups, specialized biotechnology firms, platform providers, and service organizations that together form an interconnected ecosystem. Platform providers that offer display technologies, high-throughput synthesis, and integrated screening services are central to enabling discovery throughput, while synthetic chemistry innovators and analytical specialists provide the necessary developability insights required to transition hits toward therapeutic leads. Academic spinouts and nimble biotech companies often drive early-stage novelty and application-focused innovation, translating mechanistic insights into differentiated library designs and targeting strategies.

Service organizations and contract development partners play a crucial role by allowing discovery teams to scale capacity without large upfront capital expenditure, and their geographic footprint often dictates pragmatic decisions about where key activities are executed. Meanwhile, partnerships between platform innovators and therapeutic developers are increasingly common, creating co-development pathways that accelerate tool refinement and enable mutual access to specialized expertise. In this environment, differentiation arises from the ability to deliver integrated workflows, depth of analytical validation, and a track record of translational success that spans biochemical validation through to clinical candidate selection. Companies that can demonstrate reproducible, scalable processes and transparent data pipelines command strategic relevance across discovery and development partnerships.

Practical, high-impact strategic actions leaders can implement to de-risk cyclic peptide programs and accelerate translation from discovery to clinical readiness

Industry leaders should prioritize a set of decisive actions that strengthen resilience, accelerate translational progress, and maximize the strategic value of cyclic peptide programs. First, integrate structural biology and high-quality biophysical validation at the earliest feasible stage to reduce downstream attrition and to inform rational library design. By committing resources to orthogonal validation and structural confirmation early, teams can substantially improve the signal-to-noise ratio of hit triage and focus medicinal chemistry efforts on the most promising scaffolds.

Second, diversify supply chains and consider a hybrid model that balances in-house capability with trusted external partners. Near-term procurement and tariff volatility underscore the importance of supplier redundancy and contractual flexibility. Organizations should also invest in data-centric vendor evaluation and build contingency planning into service agreements to minimize operational disruptions.

Third, cultivate cross-disciplinary teams that blend peptide chemistry, structural science, computational modeling, and translational expertise to shorten decision cycles and improve developability assessment. Equally important is the development of clear go/no-go criteria tied to both scientific milestones and business objectives, enabling objective progression decisions and conserving resources for the highest-probability programs. Finally, pursue focused partnerships and co-development arrangements that align platform strengths with therapeutic domain expertise, thereby sharing risk while unlocking complementary capabilities and accelerating time-to-proof-of-concept.

Transparent and reproducible research methodology combining primary expert interviews, technical literature synthesis, and triangulated analytical validation

This research synthesizes primary and secondary inputs with rigorous analytical frameworks to produce a balanced and reproducible view of the cyclic peptide landscape. Primary research included structured interviews with scientific and commercial leaders across academic institutions, biotechnology firms, contract service organizations, and translational research units, providing qualitative insights into technology adoption, operational challenges, and partnership dynamics. These interviews were supplemented by technical reviews of peer-reviewed literature, patent landscapes, conference proceedings, and public regulatory guidance to ground observations in documented scientific progress and policy context.

Analytical methods included cross-validation of thematic findings through triangulation, where independent data sources and expert interviews were used to corroborate key conclusions. Case-study analysis of representative discovery programs provided practical examples of workflow integration, decision gates, and translational risk management. Throughout the methodology, emphasis was placed on transparency of assumptions, reproducibility of thematic coding, and clear documentation of interview protocols and source attribution. Quality control procedures included iterative review cycles with subject-matter experts to ensure technical accuracy and to surface divergent perspectives where consensus was not present.

Synthesis of strategic imperatives and operational lessons that establish an integrated pathway for translating cyclic peptide discoveries into clinical and commercial impact

Cyclic peptide libraries stand at the intersection of chemistry, structural biology, and translational strategy, offering compelling opportunities to address challenging targets and therapeutic gaps. The evidence synthesized here shows that success depends on more than isolated technological capability; rather, it requires an integrated approach that couples robust library design, early structural validation, and operational resilience. Additionally, the external environment-from policy shifts affecting supply chains to regional differences in capability-exerts meaningful influence on program execution and partnership choices.

Looking forward, organizations that cultivate cross-disciplinary expertise, adopt flexible sourcing strategies, and engage in targeted partnerships will be better positioned to convert cyclic peptide hits into high-potential leads. By embedding structural and biophysical validation early, aligning platform selection with therapeutic context, and planning proactively for operational disruptions, stakeholders can materially improve translational outcomes. In sum, cyclic peptides are a maturing modality with distinctive advantages, and their strategic deployment requires thoughtful orchestration across science, operations, and commercial planning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cyclic Peptide Library Market, by Type

  • 8.1. Synthetic Cyclic Peptides
  • 8.2. Natural Cyclic Peptides

9. Cyclic Peptide Library Market, by Product Format

  • 9.1. Lipopeptides
  • 9.2. Cyclotides
  • 9.3. Cyclic Dipeptides

10. Cyclic Peptide Library Market, by Method

  • 10.1. Solid-Phase Peptide Synthesis
  • 10.2. Recombinant Biosynthesis
  • 10.3. Liquid-Phase Peptide Synthesis
  • 10.4. Hybrid Technology

11. Cyclic Peptide Library Market, by Route Of Administration

  • 11.1. Topical
  • 11.2. Oral
  • 11.3. Injectable

12. Cyclic Peptide Library Market, by Application

  • 12.1. Therapeutics
  • 12.2. Research & Development
  • 12.3. Environmental Protection
  • 12.4. Diagnostics & Biosensors

13. Cyclic Peptide Library Market, by End-User

  • 13.1. Pharmaceutical Companies
  • 13.2. Contract Research & Manufacturing Organizations
  • 13.3. Biotechnology Companies
  • 13.4. Academic Research Institutes

14. Cyclic Peptide Library Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cyclic Peptide Library Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cyclic Peptide Library Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cyclic Peptide Library Market

18. China Cyclic Peptide Library Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. Astellas Pharma Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bicycle Therapeutics Ltd
  • 19.9. Boehringer Ingelheim International GmbH
  • 19.10. Evotec SE
  • 19.11. Merck & Co., Inc.
  • 19.12. Novartis AG
  • 19.13. PeptiDream Inc.
  • 19.14. Pfizer Inc.
  • 19.15. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY NATURAL CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY NATURAL CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY NATURAL CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLIC DIPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLIC DIPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLIC DIPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SOLID-PHASE PEPTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SOLID-PHASE PEPTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SOLID-PHASE PEPTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RECOMBINANT BIOSYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RECOMBINANT BIOSYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RECOMBINANT BIOSYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIQUID-PHASE PEPTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIQUID-PHASE PEPTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIQUID-PHASE PEPTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY HYBRID TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY HYBRID TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY HYBRID TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY DIAGNOSTICS & BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY DIAGNOSTICS & BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY DIAGNOSTICS & BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 157. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)